Abstract

The University of Texas M.D. Anderson Cancer Center is proposing a Specialized Program of Research Excellence (SPORE) in Leukemia. The primary goal of this Leukemia SPORE is to cultivate and facilitate innovative and significant translational research in the biologic, genetic and clinical aspects of leukemia to improve understanding, therapy, and prognosis. The multidisciplinary group of investigators in the Leukemia SPORE will accomplish this goal through effective integration of laboratory, epidemiologic and clinical investigations. The SPORE is designed with 5 research projects and 3 core resources, as well as programs for developmental research and career development. The research projects are designed to target specific areas important in leukemia. Project 1 - Epigenetics and epigenetic therapy in AML Project 2 - Adoptive Cellular Therapy for Myeloid Leukemia Project 3 - p53 Activation as Novel Therapeutic Strategy for Acute Myelogenous Leukemia Project 4 - Incorporating FLT3 inhibitors into AML treatment regimens Project 5 - Development of Sepacitabine Therapy in Leukemia's Core and other resources are: Core A - Administration Core B - Pathology and Tissue Core Core C- Biostatistics and Data Management Development Research Program and Career Development Program. Through this leukemia SPORE, our research team will make a significant impact on leukemia prognosis. Lay Abstract: This leukemia SPORE integrates clinical and basic investigations to introduce new therapies in leukemia that are aimed at increasing the cure rate in this disease.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA100632-07
Application #
7683911
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (J1))
Program Officer
Nothwehr, Steven F
Project Start
2003-08-05
Project End
2013-04-30
Budget Start
2009-05-11
Budget End
2010-04-30
Support Year
7
Fiscal Year
2009
Total Cost
$2,300,000
Indirect Cost

  Institution

Name
University of Texas MD Anderson Cancer Center
Department
Internal Medicine/Medicine
Type
Other Domestic Higher Education
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030

  Publications

Xia, Fang; Ning, Jing; Huang, Xuelin (2018) Empirical Comparison of the Breslow Estimator and the Kalbfleisch Prentice Estimator for Survival Functions. J Biom Biostat 9:
Trujillo-Ocampo, Abel; Cho, Hyun-Woo; Herrmann, Amanda C et al. (2018) Rapid ex vivo expansion of highly enriched human invariant natural killer T cells via single antigenic stimulation for cell therapy to prevent graft-versus-host disease. Cytotherapy 20:1089-1101
Cortes, Jorge E; Tallman, Martin S; Schiller, Gary J et al. (2018) Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML. Blood 132:598-607
Ohanian, Maro; Rozovski, Uri; Kanagal-Shamanna, Rashmi et al. (2018) MYC protein expression is an important prognostic factor in acute myeloid leukemia. Leuk Lymphoma :1-12
Boddu, P; Jorgensen, J; Kantarjian, H et al. (2018) Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse. Leukemia 32:241-244
Yan, Fangrong; Zhu, Huihong; Liu, Junlin et al. (2018) Design and inference for 3-stage bioequivalence testing with serial sampling data. Pharm Stat 17:458-476
Kelly, Andrew D; Madzo, Jozef; Madireddi, Priyanka et al. (2018) Demethylator phenotypes in acute myeloid leukemia. Leukemia 32:2178-2188
Levis, Mark J; Perl, Alexander E; Altman, Jessica K et al. (2018) A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations. Blood Adv 2:825-831
Shah, Maitri Y; Ferracin, Manuela; Pileczki, Valentina et al. (2018) Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA CCAT2 induce myeloid malignancies via unique SNP-specific RNA mutations. Genome Res 28:432-447
Masarova, Lucia; Verstovsek, Srdan; Hidalgo-Lopez, Juliana E et al. (2018) A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. Blood 132:1664-1674

Showing the most recent 10 out of 487 publications